Background: The traditional method to determine hepatitis C (HCV) incidence requires longitudinal cohorts. However, cohort studies are challenging because they are expensive, time consuming, and may not achieve sufficient follow-up in high-risk populations such as people who inject drugs (PWIDs). The ability to detect recently infected individuals from a cross-sectional survey would reduce the need for longitudinal data. We present two HCV avidity-based tests for recent infection and compare testing algorithms to identify newly infected individuals.
Methods: Samples with previously determined HCV RNA levels from 72 PWIDs (396 samples) with known dates of infection from the Baltimore Before-and-After Acute Study of Hepatitis (BBAASH) cohort and 1,087 PWIDs (1,471 samples) infected for ≥2 years from the AIDS Linked to the Intravenous Experience (ALIVE) cohort were tested for HCV avidity by two assays: (1) the Ortho HCV 3.0 ELISA, treated with 0.25M diethylamine and (2) the Genedia HCV 3.0 ELISA, treated with 11M urea. The avidity index was the optical density ratio between treated and untreated wells. High precision of cross-sectional incidence estimation is characterized by a large mean duration of recent infection (MDRI), the average length of time that people with newly acquired infection are classified as recent, and a small false-recent rate (FRR), the proportion of non-recent infections misclassified as being recent. These properties were evaluated for 28 testing algorithms that included the two avidity assays alone at various cutoffs with and without viral load testing.
Results: At various avidity index cutoffs, the MDRI varied between 234.5–392.8 days for the Ortho 3.0 avidity assay alone and 74.5–354.0 days for the Genedia 3.0 avidity assay alone. Both avidity assays produced high FRRs, primarily due to individuals who spontaneously cleared the virus. The FRRs for the avidity assays decreased when evaluated in combination with HCV RNA confirmation, but remained above the ideal FRR of 0% (Table 1).
Conclusions: The HCV avidity and viral load testing algorithms were able to identify recently infected individuals. However, further work is needed to determine additional biomarkers that will reduce the FRRs of these testing algorithms. Efforts to optimize cross-sectional HCV incidence testing will contribute to a more practical and timely method to determine rates of new infection, yielding more rapid assessment of the epidemic and of the impact of intervention efforts.